BDBM350321 (S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1H-1,2,4-triazol-5(4H)-one::US10307414, Example 5::US11786608, Example 1::US9801872, Example 5

SMILES C=CC(=O)N1CC[C@@H](C1)Oc1nc(cc2ccccc12)-c1n[nH]c(=O)[nH]1

InChI Key InChIKey=HIMUHMBGRATXMK-UHFFFAOYSA-N

Data  13 IC50  1 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 14 hits for monomerid = 350321   

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 2nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/1/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 2nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/15/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 2nMAssay Description:Inhibition of Btk (unknown origin) assessed as inhibition of phosphorylation of FAM-labelled peptide substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2023
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataEC50:  1.30nMAssay Description:Inhibition of human Btk in human Raji cells assessed as PhosY223 measured after 30 mins by cellular HTRF assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2023
Entry Details Article
PubMed
TargetTyrosine-protein kinase Lck(Human)
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of Lck (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2023
Entry Details Article
PubMed
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 631nMAssay Description:Inhibition of Src (unknown origin)More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2023
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 0nMAssay Description:Inhibition of human Jak3More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2023
Entry Details Article
PubMed
TargetTyrosine-protein kinase Blk(Human)
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 1.26E+7nMAssay Description:Inhibition of human BlkMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2023
Entry Details Article
PubMed
TargetCytoplasmic tyrosine-protein kinase BMX(Human)
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 7.94E+7nMAssay Description:Inhibition of human BMXMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2023
Entry Details Article
PubMed
TargetTyrosine-protein kinase TXK(Human)
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 6.31E+6nMAssay Description:Inhibition of human TXKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2023
Entry Details Article
PubMed
TargetEpidermal growth factor receptor(Human)
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 0nMAssay Description:Inhibition of human EGFRMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2023
Entry Details Article
PubMed
TargetTyrosine-protein kinase ITK/TSK(Human)
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 0nMAssay Description:Inhibition of human ITKMore data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2023
Entry Details Article
PubMed
TargetReceptor tyrosine-protein kinase erbB-4(Human)
Takeda California

Curated by ChEMBL
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 2.00E+6nMAssay Description:Inhibition of human HER4More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/4/2023
Entry Details Article
PubMed
TargetTyrosine-protein kinase BTK(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM350321((S)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinol...)
Affinity DataIC50: 2nMAssay Description:The inhibitory properties of compounds relative to BTK is determined using a black 384-well-plate format in a buffer which contains 50 mM Hepes, 10 m...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2023
Entry Details
Go to US Patent